NeuroSense reports additional Phase 2 PARADIGM data for PrimeC: understanding the latest findings
July 28, 2026
PrimeC, an investigational therapy by NeuroSense Therapeutics, combines two existing prescription drugs: the antibiotic ciprofloxacin and the anti‑inflammatory drug celecoxib. Together, they are thought to target three biological processes linked to ALS: inflammation in the brain, abnormal microRNA activity (small RNA molecules that help regulate…
Continue reading